DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
LY-3009120
1
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis
Serine/threonine-protein kinase A-Raf inhibitor
LY-3009120
×
Maximum Phase:
1
First Approval:
None
UNII:
1GDT36RARO
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1,1'-METHYLENEBIS(4-((HYDROXYIMINO)METHYL)-PYRIDINIUM) DIMETHANESULFONATE
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
1,1'-METHYLENEBIS(4-((HYDROXYIMINO)METHYL)-PYRIDINIUM) DIMETHANESULFONATE
×
Maximum Phase:
1
First Approval:
None
UNII:
XV8U2XT4H7
Molecule Type:
Small molecule
Molecular Formula:
C15H20N4O8S2
Molecular Weight:
448.48
AlogP:
0.38
PSA:
72.94
HBD:
2.0
HBA:
#RotB:
4.0
Source:
CEVIPABULIN
1
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Unknown
CEVIPABULIN
×
Maximum Phase:
1
First Approval:
None
UNII:
P14M0DWS2J
Molecule Type:
Small molecule
Molecular Formula:
C18H18ClF5N6O
Molecular Weight:
464.83
AlogP:
4.07
PSA:
76.37
HBD:
2.0
HBA:
#RotB:
8.0
Source:
MITOGLITAZONE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Diabetes Mellitus, Type 2
Unknown
MITOGLITAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
29I7RP18RG
Molecule Type:
Small molecule
Molecular Formula:
C19H18N2O4S
Molecular Weight:
370.43
AlogP:
2.8
PSA:
85.36
HBD:
1.0
HBA:
#RotB:
7.0
Source:
MITEMCINAL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MITEMCINAL
×
Maximum Phase:
2
First Approval:
None
UNII:
6X5NRJ664L
Molecule Type:
Small molecule
Molecular Formula:
C40H69NO12
Molecular Weight:
755.99
AlogP:
4.53
PSA:
151.68
HBD:
2.0
HBA:
#RotB:
9.0
Source:
EVATANEPAG
2
Small molecule
Investigational
Unknown
Unknown
Tibial Fractures
Prostanoid EP2 receptor agonist
EVATANEPAG
×
Maximum Phase:
2
First Approval:
None
UNII:
L266R6E31E
Molecule Type:
Small molecule
Molecular Formula:
C25H28N2O5S
Molecular Weight:
468.58
AlogP:
4.23
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
9.0
Source:
BMS-275183
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Tubulin stabiliser
BMS-275183
×
Maximum Phase:
2
First Approval:
None
UNII:
UQC681JJIV
Molecule Type:
Small molecule
Molecular Formula:
C43H59NO16
Molecular Weight:
845.94
AlogP:
3.72
PSA:
239.75
HBD:
4.0
HBA:
#RotB:
8.0
Source:
SUVECALTAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy; Essential Tremor; Schizophrenia
Voltage-gated T-type calcium channel modulator
SUVECALTAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
MIA4WMP8QN
Molecule Type:
Small molecule
Molecular Formula:
C20H23F3N2O2
Molecular Weight:
380.41
AlogP:
4.57
PSA:
51.22
HBD:
1.0
HBA:
#RotB:
7.0
Source:
VALATEGRAST
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Unknown
VALATEGRAST
×
Maximum Phase:
2
First Approval:
None
UNII:
06DM4KX7JG
Molecule Type:
Small molecule
Molecular Formula:
C30H32Cl3N3O4
Molecular Weight:
604.96
AlogP:
6.43
PSA:
87.74
HBD:
2.0
HBA:
#RotB:
12.0
Source:
MAVELERTINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
MAVELERTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
YXX2180047
Molecule Type:
Small molecule
Molecular Formula:
C18H22FN9O2
Molecular Weight:
415.43
AlogP:
0.68
PSA:
115.02
HBD:
2.0
HBA:
#RotB:
6.0
Source:
LY2940094
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Alcoholism; Depressive Disorder, Major
Nociceptin receptor antagonist
LY2940094
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SELODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation
Adenosine A1 receptor agonist
SELODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
103G5E953K
Molecule Type:
Small molecule
Molecular Formula:
C17H24N6O4
Molecular Weight:
376.42
AlogP:
-0.06
PSA:
134.42
HBD:
4.0
HBA:
#RotB:
5.0
Source:
ENMD-981693
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Pancreatic Neoplasms
Fibroblast growth factor receptor inhibitor
ENMD-981693
×
Maximum Phase:
2
First Approval:
None
UNII:
DNZ11VPY7Q
Molecule Type:
Small molecule
Molecular Formula:
C22H16N4O4
Molecular Weight:
400.39
AlogP:
3.15
PSA:
99.17
HBD:
1.0
HBA:
#RotB:
3.0
Source:
DS107G
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DS107G
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVN-944
2
Small molecule
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
AVN-944
×
Maximum Phase:
2
First Approval:
None
UNII:
I3NPL1V48Q
Molecule Type:
Small molecule
Molecular Formula:
C25H27N5O5
Molecular Weight:
477.52
AlogP:
5.47
PSA:
138.51
HBD:
3.0
HBA:
#RotB:
9.0
Source:
NELOTANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Hallucinations; Lewy Body Disease; Sleep Initiation and Maintenance Disorders
Serotonin 2a (5-HT2a) receptor inverse agonist
NELOTANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
4ZA73QEW2P
Molecule Type:
Small molecule
Molecular Formula:
C18H15BrF2N4O2
Molecular Weight:
437.24
AlogP:
4.78
PSA:
68.18
HBD:
2.0
HBA:
#RotB:
4.0
Source:
KRN5500
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Neuralgia
Unknown
KRN5500
×
Maximum Phase:
2
First Approval:
None
UNII:
8VH13L5K20
Molecule Type:
Small molecule
Molecular Formula:
C28H43N7O7
Molecular Weight:
589.69
AlogP:
0.42
PSA:
214.84
HBD:
8.0
HBA:
#RotB:
17.0
Source:
GENISTEIN
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Cystic Fibrosis; Neoplasms; Rectal Neoplasms; Breast Neoplasms; Coronary Disease; Metabolic Syndrome; Osteoporosis; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pulmonary Fibrosis; Urinary Bladder Neoplasms
Unknown
GENISTEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DH2M523P0H
Molecule Type:
Small molecule
Molecular Formula:
C15H10O5
Molecular Weight:
270.24
AlogP:
2.58
PSA:
90.9
HBD:
3.0
HBA:
#RotB:
1.0
Source:
PF-04691502
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms
PI3-kinase class I inhibitor
PF-04691502
×
Maximum Phase:
2
First Approval:
None
UNII:
4W39NS61KI
Molecule Type:
Small molecule
Molecular Formula:
C22H27N5O4
Molecular Weight:
425.49
AlogP:
2.25
PSA:
125.38
HBD:
2.0
HBA:
#RotB:
6.0
Source:
BMS-906024
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Breast Neoplasms; Carcinoma, Adenoid Cystic
Unknown
BMS-906024
×
Maximum Phase:
2
First Approval:
None
UNII:
DRL23N424R
Molecule Type:
Small molecule
Molecular Formula:
C26H26F6N4O3
Molecular Weight:
556.51
AlogP:
4.35
PSA:
104.86
HBD:
2.0
HBA:
#RotB:
9.0
Source:
DAR-0100A
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DAR-0100A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PD-217014
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome; Pain
Unknown
PD-217014
×
Maximum Phase:
2
First Approval:
None
UNII:
K2T93E812G
Molecule Type:
Small molecule
Molecular Formula:
C11H19NO2
Molecular Weight:
197.28
AlogP:
1.31
PSA:
52.32
HBD:
1.0
HBA:
#RotB:
3.0
Source:
LY2245461
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Estrogen receptor modulator
LY2245461
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARBACLOFEN PLACARBIL
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Back Pain; Gastroesophageal Reflux; Muscle Spasticity; Multiple Sclerosis
GABA-B receptor agonist
ARBACLOFEN PLACARBIL
×
Maximum Phase:
2
First Approval:
None
UNII:
W89H91R7VX
Molecule Type:
Small molecule
Molecular Formula:
C19H26ClNO6
Molecular Weight:
399.87
AlogP:
3.81
PSA:
101.93
HBD:
2.0
HBA:
#RotB:
9.0
Source:
DENAGLIPTIN TOSYLATE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
DENAGLIPTIN TOSYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
T47477CUF7
Molecule Type:
Small molecule
Molecular Formula:
C27H26F3N3O4S
Molecular Weight:
545.58
AlogP:
2.89
PSA:
70.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
HPPH
2
Small molecule
Investigational
Unknown
Unknown
Adenocarcinoma of Lung; Barrett Esophagus; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Esophageal Neoplasms; Lung Neoplasms; Oropharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck
Unknown
HPPH
×
Maximum Phase:
2
First Approval:
None
UNII:
DOB7Y3RSX0
Molecule Type:
Small molecule
Molecular Formula:
C39H48N4O4
Molecular Weight:
636.84
AlogP:
9.42
PSA:
120.96
HBD:
3.0
HBA:
#RotB:
11.0
Source:
MK-0457
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MK-0457
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCITANIB
2
Small molecule
Investigational
Unknown
Unknown
Genital Neoplasms, Female; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Small Cell Lung Carcinoma
Fibroblast growth factor receptor 1 inhibitor
LUCITANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
PP449XA4BH
Molecule Type:
Small molecule
Molecular Formula:
C26H25N3O4
Molecular Weight:
443.5
AlogP:
4.42
PSA:
95.7
HBD:
2.0
HBA:
#RotB:
7.0
Source:
SOVAPREVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus serine protease, NS3/NS4A inhibitor
SOVAPREVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
2ND9V3MN6O
Molecule Type:
Small molecule
Molecular Formula:
C43H53N5O8S
Molecular Weight:
799.99
AlogP:
4.99
PSA:
164.31
HBD:
2.0
HBA:
#RotB:
13.0
Source:
BAICALEIN
2
Small molecule
Investigational
Unknown
Unknown
Influenza, Human
Unknown
BAICALEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
49QAH60606
Molecule Type:
Small molecule
Molecular Formula:
C15H10O5
Molecular Weight:
270.24
AlogP:
2.58
PSA:
90.9
HBD:
3.0
HBA:
#RotB:
1.0
Source:
LERIGLITAZONE
2
Small molecule
Investigational
Unknown
Unknown
Friedreich Ataxia
Peroxisome proliferator-activated receptor gamma agonist
LERIGLITAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
K824X25AYA
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O4S
Molecular Weight:
372.45
AlogP:
2.65
PSA:
88.52
HBD:
2.0
HBA:
#RotB:
7.0
Source:
NAVARIXIN
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Psoriasis; Pulmonary Disease, Chronic Obstructive
Interleukin-8 receptor A antagonist
NAVARIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
7V3BY6G538
Molecule Type:
Small molecule
Molecular Formula:
C21H23N3O5
Molecular Weight:
397.43
AlogP:
2.9
PSA:
111.88
HBD:
3.0
HBA:
#RotB:
7.0
Source:
IBERDOMIDE
2
Small molecule
Investigational
Unknown
Unknown
Renal Insufficiency; Multiple Myeloma
CRL4(CRBN) E3 ubiquitin ligase modulator
IBERDOMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
8V66F27X44
Molecule Type:
Small molecule
Molecular Formula:
C25H27N3O5
Molecular Weight:
449.51
AlogP:
1.86
PSA:
88.18
HBD:
1.0
HBA:
#RotB:
6.0
Source:
E-FLUPENTIXOL
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Substance-Related Disorders
Unknown
E-FLUPENTIXOL
×
Maximum Phase:
2
First Approval:
None
UNII:
895OJP78MJ
Molecule Type:
Small molecule
Molecular Formula:
C23H25F3N2OS
Molecular Weight:
434.53
AlogP:
4.6
PSA:
26.71
HBD:
1.0
HBA:
#RotB:
5.0
Source:
GSK-2636771
2
Small molecule
Investigational
Unknown
Unknown
Melanoma; Neoplasms; Stomach Neoplasms; Multiple Myeloma
PI3-kinase p110-beta subunit inhibitor
GSK-2636771
×
Maximum Phase:
2
First Approval:
None
UNII:
DW94IAT0LS
Molecule Type:
Small molecule
Molecular Formula:
C22H22F3N3O3
Molecular Weight:
433.43
AlogP:
4.26
PSA:
67.59
HBD:
1.0
HBA:
#RotB:
4.0
Source:
1
2
…
86
87
88
89
90
91
92
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA